

Technical Bulletin

Changes to Urine Hydrocodone toxicology



Effective September 5, 2023, Hydrocodone in house testing will no longer be performed at the Methodist Laboratories (Methodist Hospital Pathology Center, Methodist Women's Hospital, Methodist Jennie Edmundson Hospital).

This change is due to cross reactivity observed with the in-house assay that was deemed unacceptable upon review.

The testing for urine hydrocodone will be switched to a send out test at our reference laboratory (ARUP).

Remaining components remain unchanged and include cannabinoid (THC), cocaine, opiates, amphetamines, barbiturates, benzodiazepines, and oxycodone.

The drugs of abuse screen does NOT detect meperidine, methadone, fentanyl, GHB, and propoxyphene, among other medications.

Urine Toxicology Screen testing is intended for MEDICAL purposes only.

In cases where identity or class of the drug or drugs of interest is not known or the in house urine drug screen doesn't detect the drug of interest, please consider additional testing at reference laboratory utilizing Gas Chromatography-Mass Spectrometry/Liquid Chromatography-Tandem Mass Spectrometry methodologies (ARUP test 0090364).

Additional testing and confirmatory testing can be performed upon request.

Change: Hydrocodone urine screen switched to send out test.

Order: Toxicology Screen DAU (Drugs of Abuse Screen) (123238)

Specimen Requirements: 4mL well-mixed urine (random), minimum 2mL. Refrigerate 2-8°C

Please direct any questions to Dr. George Bedrnicek at 402 955-5528 or to Dr. Deborah Perry at 402 354-4559.